Viking Therapeutics Seeks $400 Million to Accelerate Obesity Drug Pipeline

The offering consists of $200 million in common stock and $200 million in convertible senior notes due in 2032. Underwriters will receive 30-day options for an additional $30 million in each category to cover potential over-allotments. The company noted that the completion of either offering is not contingent upon the other, providing flexibility as they navigate market conditions. Morgan Stanley & Co. LLC and J.P. Morgan Securities LLC are managing the offerings.

The convertible notes will function as senior, unsecured obligations. Holders may convert these into cash, common stock, or a mix of both, depending on Viking’s election. Redemption options for the company begin in October 2029, provided the stock price maintains a specific threshold relative to the conversion price. If fundamental corporate changes occur, noteholders retain the right to require repurchase.

Proceeds are earmarked for the advancement of the VK2735 program, currently in Phase 3 trials for obesity, and the development of the VK3019 amylin receptor agonist. These moves follow a broader industry trend of biotech firms securing capital to capitalize on the high demand for metabolic and endocrine disorder treatments.